Diluted EPS of $1.31
MURRAY HILL, N.J.--(BUSINESS WIRE)--Oct. 21, 2009--
C. R. Bard, Inc. (NYSE: BCR) today reported 2009 third quarter financial
results. Third quarter 2009 net sales were $637.0 million, an increase
of 3 percent over the prior-year period. Excluding the impact of foreign
exchange, third quarter 2009 net sales increased 6 percent over the
prior-year period.
For the third quarter 2009, net sales in the U.S. were $442.6 million
and net sales outside the U.S. were $194.4 million, an increase of 6
percent and a decrease of 1 percent, respectively, over the prior-year
period. Excluding the impact of foreign exchange, third quarter 2009 net
sales outside the U.S. increased 7 percent over the prior-year period.
For the third quarter 2009, net income attributable to common
shareholders was $129.5 million and diluted earnings per share available
to common shareholders were $1.31, an increase of 16 percent and 21
percent, respectively, as compared to third quarter 2008 results.
Adjusting for items that affect comparability between periods as
detailed in the tables below, third quarter 2009 net income attributable
to common shareholders and diluted earnings per share available to
common shareholders increased 15 percent and 20 percent, respectively,
as compared to third quarter 2008 results.
Timothy M. Ring, chairman and chief executive officer, commented, “Bard
delivered another quarter of strong EPS performance while funding a
record level of organic investment in R&D. We remain focused on the
future through the development and acquisition of products that are
differentiated by their clinical and economic benefits. We believe that
superior technology is key to improving the lives of patients and
sustaining a product leadership position in the market.”
C. R. Bard, Inc. (www.crbard.com),
headquartered in Murray Hill, NJ, is a leading multinational developer,
manufacturer and marketer of innovative, life-enhancing medical
technologies in the fields of vascular, urology, oncology and surgical
specialty products.
This press release may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, which
are based on management’s current expectations, the accuracy of which is
necessarily subject to risks and uncertainties. These statements are not
historical in nature and use words such as “anticipate”, “estimate”,
“expect”, “project”, “intend”, “forecast”, “plan”, “believe”, and other
words of similar meaning in connection with any discussion of future
operating or financial performance. Many factors may cause actual
results to differ materially from anticipated results including product
developments, sales efforts, income tax matters, the outcomes of
contingencies such as legal proceedings, and other economic, business,
competitive and regulatory factors. The company undertakes no obligation
to update its forward-looking statements. Please refer to the Cautionary
Statement Regarding Forward-Looking Information in our June 30, 2009
Form 10-Q for more detailed information about these and other factors
that may cause actual results to differ materially from those expressed
or implied.
|
C. R. Bard, Inc.
|
|
Consolidated Statements of Income
|
|
(dollars and shares in thousands except per share amounts, unaudited)
|
|
|
|
|
|
Quarter Ended
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
September 30,
|
|
|
|
2009
|
|
2008
|
|
2009
|
|
2008
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
$
|
637,000
|
|
$
|
616,800
|
|
|
$
|
1,858,000
|
|
$
|
1,817,900
|
|
Costs and expenses
|
|
|
|
|
|
|
|
|
|
Cost of goods sold
|
|
|
240,900
|
|
|
238,600
|
|
|
|
703,800
|
|
|
706,700
|
|
Marketing, selling and administrative expense
|
|
|
164,300
|
|
|
180,600
|
|
|
|
498,500
|
|
|
530,300
|
|
Research and development expense
|
|
|
43,000
|
|
|
35,100
|
|
|
|
121,100
|
|
|
159,100
|
|
Interest expense
|
|
|
3,000
|
|
|
3,100
|
|
|
|
9,000
|
|
|
9,100
|
|
Other (income) expense, net
|
|
|
600
|
|
|
(1,900
|
)
|
|
|
17,500
|
|
|
26,700
|
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses
|
|
|
451,800
|
|
|
455,500
|
|
|
|
1,349,900
|
|
|
1,431,900
|
|
Income from operations before income taxes
|
|
|
185,200
|
|
|
161,300
|
|
|
|
508,100
|
|
|
386,000
|
|
|
|
|
|
|
|
|
|
|
|
Income tax provision
|
|
|
55,200
|
|
|
49,200
|
|
|
|
152,500
|
|
|
117,000
|
|
Net income
|
|
|
130,000
|
|
|
112,100
|
|
|
|
355,600
|
|
|
269,000
|
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to noncontrolling interest
|
|
|
500
|
|
|
900
|
|
|
|
1,400
|
|
|
1,900
|
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to common shareholders
|
|
$
|
129,500
|
|
$
|
111,200
|
|
|
$
|
354,200
|
|
$
|
267,100
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per share available to common shareholders (1)
|
|
$
|
1.32
|
|
$
|
1.10
|
|
|
$
|
3.57
|
|
$
|
2.64
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share available to common shareholders (1)
|
|
$
|
1.31
|
|
$
|
1.08
|
|
|
$
|
3.52
|
|
$
|
2.59
|
|
|
|
|
|
|
|
|
|
|
|
Wt. avg. common shares outstanding - basic
|
|
|
97,000
|
|
|
99,300
|
|
|
|
98,200
|
|
|
99,600
|
|
|
|
|
|
|
|
|
|
|
|
Wt. avg. common and common equivalent shares outstanding - diluted
|
|
|
98,100
|
|
|
101,300
|
|
|
|
99,500
|
|
|
101,700
|
(1) Reflects the retrospective adoption of the FASB Staff Position (the
"FSP"), determining whether awards granted in share-based payment
transactions are participating securities. See Notes to Earnings per
Share included within this press release for additional information.
|
Product Group Summary of Net Sales
|
|
(dollars in thousands, unaudited)
|
|
|
|
|
|
Quarter Ended September 30,
|
|
|
|
Nine Months Ended September 30,
|
|
|
|
|
|
|
|
|
|
Constant
|
|
|
|
|
|
|
|
|
|
Constant
|
|
|
|
2009
|
|
2008
|
|
Change
|
|
Currency
|
|
|
|
2009
|
|
2008
|
|
Change
|
|
Currency
|
|
Vascular
|
|
$
|
173,600
|
|
$
|
160,600
|
|
|
8%
|
|
13%
|
|
|
|
$
|
500,100
|
|
$
|
474,600
|
|
|
5%
|
|
12%
|
|
Urology
|
|
|
177,500
|
|
|
174,500
|
|
|
2%
|
|
4%
|
|
|
|
|
515,000
|
|
|
519,600
|
|
|
-1%
|
|
2%
|
|
Oncology
|
|
|
171,600
|
|
|
169,300
|
|
|
1%
|
|
3%
|
|
|
|
|
499,800
|
|
|
483,000
|
|
|
3%
|
|
6%
|
|
Surgical Specialties
|
|
|
93,100
|
|
|
90,800
|
|
|
3%
|
|
5%
|
|
|
|
|
279,100
|
|
|
272,700
|
|
|
2%
|
|
6%
|
|
Other
|
|
|
21,200
|
|
|
21,600
|
|
|
-2%
|
|
-
|
|
|
|
|
64,000
|
|
|
68,000
|
|
|
-6%
|
|
-2%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
$
|
637,000
|
|
$
|
616,800
|
|
|
3%
|
|
|
|
|
|
$
|
1,858,000
|
|
$
|
1,817,900
|
|
|
2%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange impact
|
|
|
|
|
(15,700
|
)
|
|
|
|
|
|
|
|
|
|
|
(67,300
|
)
|
|
|
|
|
|
Constant Currency
|
|
$
|
637,000
|
|
$
|
601,100
|
|
|
|
|
6%
|
|
|
|
$
|
1,858,000
|
|
$
|
1,750,600
|
|
|
|
|
6%
|
|
Reconciliation of Earnings
|
|
(dollars in millions except per share amounts, unaudited)
|
|
|
|
|
|
Quarter Ended September 30, 2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
|
|
Earnings
|
|
|
|
|
|
Marketing,
|
|
|
|
|
|
|
|
Income
|
|
per Share
|
|
|
|
Cost of
|
|
Selling and
|
|
Research &
|
|
Other
|
|
|
|
Attributable
|
|
Available
|
|
|
|
Goods
|
|
Administrative
|
|
Development
|
|
(Income)
|
|
Income
|
|
to Common
|
|
to Common
|
|
|
|
Sold
|
|
Expense
|
|
Expense
|
|
Expense, Net
|
|
Taxes
|
|
Shareholders
|
|
Shareholders (1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Basis
|
|
$
|
240.9
|
|
|
$
|
164.3
|
|
|
$
|
43.0
|
|
|
$
|
0.6
|
|
|
$
|
55.2
|
|
|
$
|
129.5
|
|
|
$
|
1.31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted Basis
|
|
$
|
240.9
|
|
|
$
|
164.3
|
|
|
$
|
43.0
|
|
|
$
|
0.6
|
|
|
$
|
55.2
|
|
|
$
|
129.5
|
|
|
$
|
1.31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended September 30, 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
|
|
Earnings
|
|
|
|
|
|
Marketing,
|
|
|
|
|
|
|
|
Income
|
|
per Share
|
|
|
|
Cost of
|
|
Selling and
|
|
Research &
|
|
Other
|
|
|
|
Attributable
|
|
Available
|
|
|
|
Goods
|
|
Administrative
|
|
Development
|
|
(Income)
|
|
Income
|
|
to Common
|
|
to Common
|
|
|
|
Sold
|
|
Expense
|
|
Expense
|
|
Expense, Net
|
|
Taxes
|
|
Shareholders
|
|
Shareholders (1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Basis
|
|
$
|
238.6
|
|
|
$
|
180.6
|
|
|
$
|
35.1
|
|
|
$
|
(1.9
|
)
|
|
$
|
49.2
|
|
|
$
|
111.2
|
|
|
$
|
1.08
|
|
Items that affect comparability of
results between periods:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reorganization costs
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(1.3
|
)
|
|
|
0.5
|
|
|
|
0.8
|
|
|
|
|
Gain on asset sale
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0.7
|
|
|
|
(0.1
|
)
|
|
|
(0.6
|
)
|
|
|
|
Tax adjustment
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(1.0
|
)
|
|
|
1.0
|
|
|
|
|
Total
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(0.6
|
)
|
|
|
(0.6
|
)
|
|
|
1.2
|
|
|
|
0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted Basis
|
|
$
|
238.6
|
|
|
$
|
180.6
|
|
|
$
|
35.1
|
|
|
$
|
(2.5
|
)
|
|
$
|
48.6
|
|
|
$
|
112.4
|
|
|
$
|
1.09
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, 2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
|
|
Earnings
|
|
|
|
|
|
Marketing,
|
|
|
|
|
|
|
|
Income
|
|
per Share
|
|
|
|
Cost of
|
|
Selling and
|
|
Research &
|
|
Other
|
|
|
|
Attributable
|
|
Available
|
|
|
|
Goods
|
|
Administrative
|
|
Development
|
|
(Income)
|
|
Income
|
|
to Common
|
|
to Common
|
|
|
|
Sold
|
|
Expense
|
|
Expense
|
|
Expense, Net
|
|
Taxes
|
|
Shareholders
|
|
Shareholders (1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Basis
|
|
$
|
703.8
|
|
|
$
|
498.5
|
|
|
$
|
121.1
|
|
|
$
|
17.5
|
|
|
$
|
152.5
|
|
|
$
|
354.2
|
|
|
$
|
3.52
|
|
Items that affect comparability of
results between periods:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Asset disposition
|
|
|
(1.2
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
(4.5
|
)
|
|
|
0.5
|
|
|
|
5.2
|
|
|
|
|
Acquisition related adjustments
|
|
|
(0.1
|
)
|
|
|
(0.8
|
)
|
|
|
(2.3
|
)
|
|
|
-
|
|
|
|
0.1
|
|
|
|
3.1
|
|
|
|
|
Restructuring charge
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(15.4
|
)
|
|
|
5.2
|
|
|
|
10.2
|
|
|
|
|
Total
|
|
|
(1.3
|
)
|
|
|
(0.8
|
)
|
|
|
(2.3
|
)
|
|
|
(19.9
|
)
|
|
|
5.8
|
|
|
|
18.5
|
|
|
|
0.18
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted Basis
|
|
$
|
702.5
|
|
|
$
|
497.7
|
|
|
$
|
118.8
|
|
|
$
|
(2.4
|
)
|
|
$
|
158.3
|
|
|
$
|
372.7
|
|
|
$
|
3.70
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
|
|
Earnings
|
|
|
|
|
|
Marketing,
|
|
|
|
|
|
|
|
Income
|
|
per Share
|
|
|
|
Cost of
|
|
Selling and
|
|
Research &
|
|
Other
|
|
|
|
Attributable
|
|
Available
|
|
|
|
Goods
|
|
Administrative
|
|
Development
|
|
(Income)
|
|
Income
|
|
to Common
|
|
to Common
|
|
|
|
Sold
|
|
Expense
|
|
Expense
|
|
Expense, Net
|
|
Taxes
|
|
Shareholders
|
|
Shareholders (1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Basis
|
|
$
|
706.7
|
|
|
$
|
530.3
|
|
|
$
|
159.1
|
|
|
$
|
26.7
|
|
|
$
|
117.0
|
|
|
$
|
267.1
|
|
|
$
|
2.59
|
|
Items that affect comparability of
results between periods:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Asset disposition
|
|
|
(3.7
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
(36.8
|
)
|
|
|
5.6
|
|
|
|
34.9
|
|
|
|
|
Acquisition related adjustments
|
|
|
-
|
|
|
|
-
|
|
|
|
(49.3
|
)
|
|
|
-
|
|
|
|
18.2
|
|
|
|
31.1
|
|
|
|
|
Reorganization costs
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(1.3
|
)
|
|
|
0.5
|
|
|
|
0.8
|
|
|
|
|
Gain on asset sale
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0.7
|
|
|
|
(0.1
|
)
|
|
|
(0.6
|
)
|
|
|
|
Tax adjustment
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(1.0
|
)
|
|
|
1.0
|
|
|
|
|
Total
|
|
|
(3.7
|
)
|
|
|
-
|
|
|
|
(49.3
|
)
|
|
|
(37.4
|
)
|
|
|
23.2
|
|
|
|
67.2
|
|
|
|
0.65
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted Basis
|
|
$
|
703.0
|
|
|
$
|
530.3
|
|
|
$
|
109.8
|
|
|
$
|
(10.7
|
)
|
|
$
|
140.2
|
|
|
$
|
334.3
|
|
|
$
|
3.24
|
(1) Reflects the retrospective adoption of the FSP. See Notes to
Earnings per Share included within this press release for additional
information.
Notes to Reconciliation of Earnings
-
For the third quarter 2008, the following items affected the
comparability of results between periods: (i) a charge of $1.3 million
pre-tax for reorganization costs; (ii) a gain of $0.7 million pre-tax
associated with the sale of an asset; and (iii) an increase of $1.0
million in the income tax provision due to a tax-related interest
adjustment. The net effect of these items decreased net income
attributable to common shareholders by $1.2 million, or $0.01 diluted
earnings per share available to common shareholders.
-
For the nine months ended September 30, 2009, the following items
affected the comparability of results between periods: (i) a charge of
$5.7 million pre-tax for an asset disposition; (ii) charges of $3.2
million pre-tax for acquisition related adjustments including
purchased research and development and other transaction costs
consisting primarily of legal and valuation costs directly related to
acquisition activities; and (iii) a charge of $15.4 million pre-tax
for restructuring. The net effect of these items decreased net income
attributable to common shareholders by $18.5 million, or $0.18 diluted
earnings per share available to common shareholders.
-
For the nine months ended September 30, 2008, the following items
affected the comparability of results between periods: (i) a charge of
$40.5 million pre-tax for an asset disposition; (ii) a charge of $49.3
million pre-tax for acquisition related adjustments consisting of
purchased research and development; (iii) a charge of $1.3 million
pre-tax for reorganization costs; (iv) a gain of $0.7 million pre-tax
associated with the sale of an asset; and (v) an increase of $1.0
million in the income tax provision due to a tax-related interest
adjustment. The net effect of these items decreased net income
attributable to common shareholders by $67.2 million, or $0.65 diluted
earnings per share available to common shareholders.
This press release contains financial measures that are not calculated
in accordance with United States generally accepted accounting
principles (GAAP). These non-GAAP financial measures are reconciled to
their most directly comparable GAAP measures in the above tables.
This press release includes net sales excluding the impact of foreign
exchange. The company analyzes net sales on a constant currency basis to
better measure the comparability of results between periods. Because
changes in foreign currency exchange rates have a non-operating impact
on net sales, the company believes that evaluating growth in net sales
on a constant currency basis provides an additional and meaningful
assessment of net sales to both management and the company’s investors.
In addition, this press release includes the following non-GAAP
measures: (1) cost of goods sold excluding charges for asset
dispositions and acquisition related adjustments; (2) marketing, selling
and administrative expenses excluding acquisition related adjustments;
(3) research & development expense excluding acquisition related
adjustments; (4) other (income) expense, net, excluding charges for
asset dispositions, restructuring charge, reorganization costs and a
gain on an asset sale; (5) income tax provision excluding an increase
related to a tax-related interest adjustment and the tax effect of the
items set forth in (1) through (4) above; (6) net income attributable to
common shareholders excluding the items set forth in (1) through (5)
above; and (7) diluted earnings per share available to common
shareholders excluding the items set forth in (1) through (5) above.
The company excluded the items described above because they may cause
certain statements of income categories not to be indicative of ongoing
operating results, and therefore affect the comparability of results
between periods. The company therefore believes that these non-GAAP
measures provide an additional and meaningful assessment of the
company’s ongoing operating performance. Because the company has
historically reported these non-GAAP results to the investment
community, management also believes that the inclusion of these non-GAAP
measures provides consistency in its financial reporting and facilitates
investors’ understanding of the company’s historic operating trends by
providing an additional basis for comparisons to prior periods.
Management uses these non-GAAP measures: (1) to establish financial and
operational goals; (2) to monitor the company’s actual performance in
relation to its business plan and operating budgets; (3) to evaluate the
company’s core operating performance and understand key trends within
the business; and (4) as part of several components it considers in
determining incentive compensation.
Management recognizes that the use of these non-GAAP measures has
limitations, including the fact that they may not be comparable with
similar non-GAAP financial measures used by other companies and that
management must exercise judgment in determining which types of charges
or other items should be excluded from the non-GAAP financial
information. Management compensates for these limitations by providing
full disclosure of each non-GAAP financial measure and a reconciliation
to the most directly comparable GAAP financial measure. All non-GAAP
financial measures are intended to supplement the applicable GAAP
disclosures and should not be considered in isolation from, or as a
replacement for, financial information prepared in accordance with GAAP.
For a reconciliation of these non-GAAP measures to the most comparable
GAAP measures, please see the above tables.
|
Notes to Earnings per Share
(dollars and shares in thousands, except per share amounts,
unaudited)
|
|
|
|
|
|
Quarter Ended
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
September 30,
|
|
|
|
2009
|
|
2008
|
|
2009
|
|
2008
|
|
Earnings per Share Numerator (1): GAAP Basis - basic and diluted
|
|
|
|
|
|
|
|
|
|
Net income attributable to common shareholders
|
|
$
|
129,500
|
|
$
|
111,200
|
|
$
|
354,200
|
|
$
|
267,100
|
|
Less: Income allocated to participating securities
|
|
|
1,300
|
|
|
1,600
|
|
|
3,900
|
|
|
3,700
|
|
Net income available to common shareholders
|
|
$
|
128,200
|
|
$
|
109,600
|
|
$
|
350,300
|
|
$
|
263,400
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per Share Numerator (1): Adjusted Basis - diluted
|
|
|
|
|
|
|
|
|
|
Net income attributable to common shareholders
|
|
$
|
129,500
|
|
$
|
112,400
|
|
$
|
372,700
|
|
$
|
334,300
|
|
Less: Income allocated to participating securities
|
|
|
1,300
|
|
|
1,600
|
|
|
4,100
|
|
|
4,600
|
|
Net income available to common shareholders
|
|
$
|
128,200
|
|
$
|
110,800
|
|
$
|
368,600
|
|
$
|
329,700
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per Share Denominator:
|
|
|
|
|
|
|
|
|
|
Wt. avg. common shares outstanding - basic
|
|
|
97,000
|
|
|
99,300
|
|
|
98,200
|
|
|
99,600
|
|
|
|
|
|
|
|
|
|
|
|
Wt. avg. common and common equivalent shares outstanding - diluted
|
|
|
98,100
|
|
|
101,300
|
|
|
99,500
|
|
|
101,700
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per Share: GAAP Basis
|
|
|
|
|
|
|
|
|
|
Basic earnings per share available to common shareholders
|
|
$
|
1.32
|
|
$
|
1.10
|
|
$
|
3.57
|
|
$
|
2.64
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share available to common shareholders
|
|
$
|
1.31
|
|
$
|
1.08
|
|
$
|
3.52
|
|
$
|
2.59
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per Share: Adjusted Basis
|
|
|
|
|
|
|
|
|
|
Diluted earnings per share available to common shareholders
|
|
$
|
1.31
|
|
$
|
1.09
|
|
$
|
3.70
|
|
$
|
3.24
|
(1) Basic and diluted earnings per share available to common
shareholders is calculated using a numerator, which represents the total
of net income attributable to common shareholders less income allocated
to participating securities under the FSP.
Source: C. R. Bard, Inc.
C. R. Bard, Inc. Investor Relations: Eric J.
Shick, 908-277-8413 Vice President, Investor Relations or Media
Relations: Scott T. Lowry, 908-277-8365 Vice
President and Treasurer
|